A detailed history of Armistice Capital, LLC transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, Armistice Capital, LLC holds 2,207,070 shares of AGIO stock, worth $130 Million. This represents 1.63% of its overall portfolio holdings.

Number of Shares
2,207,070
Previous 2,079,151 6.15%
Holding current value
$130 Million
Previous $89.7 Million 9.38%
% of portfolio
1.63%
Previous 1.17%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$41.19 - $49.72 $5.27 Million - $6.36 Million
127,919 Added 6.15%
2,207,070 $98.1 Million
Q2 2024

Aug 14, 2024

SELL
$27.55 - $48.83 $24.4 Million - $43.2 Million
-884,849 Reduced 29.85%
2,079,151 $89.7 Million
Q1 2024

May 15, 2024

SELL
$21.32 - $34.81 $11.9 Million - $19.5 Million
-560,000 Reduced 15.89%
2,964,000 $86.7 Million
Q4 2023

Feb 13, 2024

BUY
$19.97 - $24.53 $3.99 Million - $4.91 Million
200,000 Added 6.02%
3,524,000 $78.5 Million
Q3 2023

Nov 14, 2023

BUY
$24.36 - $28.18 $1.66 Million - $1.92 Million
68,000 Added 2.09%
3,324,000 $82.3 Million
Q2 2023

Aug 14, 2023

SELL
$21.38 - $29.19 $4.36 Million - $5.95 Million
-204,000 Reduced 5.9%
3,256,000 $92.2 Million
Q1 2023

May 15, 2023

BUY
$21.74 - $30.93 $15.4 Million - $22 Million
710,000 Added 25.82%
3,460,000 $79.5 Million
Q4 2022

Feb 14, 2023

BUY
$24.81 - $31.52 $20.5 Million - $26 Million
826,000 Added 42.93%
2,750,000 $77.2 Million
Q3 2022

Nov 14, 2022

BUY
$19.51 - $34.14 $37.5 Million - $65.7 Million
1,924,000 New
1,924,000 $54.4 Million

Others Institutions Holding AGIO

About AGIOS PHARMACEUTICALS, INC.


  • Ticker AGIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,818,000
  • Market Cap $3.23B
  • Description
  • Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...
More about AGIO
Track This Portfolio

Track Armistice Capital, LLC Portfolio

Follow Armistice Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Armistice Capital, LLC with notifications on news.